OA-45 Pharmacokinetic and correlative analysis of ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma in the CARTITUDE-4 trial
Carlos Fernández de Larrea(Hospital Clínic de Barcelona), Christopher Strouse(University of Iowa Hospitals and Clinics), Nitin Patel(Centro de Investigación del Cáncer), Reuben Benjamin(King's College London), Dominik Dytfeld, María‐Victoria Mateos(Hospital Clínico San Carlos), Niels W.C.J. van de Donk(Oncode Institute), Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), Diana Chen(Johnson Electric (China)), Paolo Corradini(Gruppo di Ricerca Geriatrica), Albert Oriol(Institut Català d'Oncologia), Arnob Banerjee(Johnson & Johnson (United States)), Duncan Purtill(Fiona Stanley Hospital), Carolina Lonardi(Janssen (Switzerland)), Michèle Cavo(Unknown), Ana Slaughter(Centro de Investigación del Cáncer), Jordan M. Schecter(Centro de Investigación del Cáncer), William Deraedt(Janssen (Belgium)), Simon J. Harrison(Peter MacCallum Cancer Centre), Tzu‐Min Yeh(Centro de Investigación del Cáncer), Chang‐Ki Min(The Catholic University of Korea Seoul St. Mary's Hospital), Katherine Li(Centro de Investigación del Cáncer), Shirley Shih-Yu Chang, Dong Geng, Pharavee Jaiprasart
Cited by 3
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k